This review comprises the pharmacokinetics and pharmacodynamics of natural and
synthetic estrogens and progestogens used in contraception and therapy, with special …

Background Acne is a common skin disorder among women. Although no uniform approach
to the management of acne exists, combination oral contraceptives (COCs), which contain …

The pharmacology and pharmacokinetics of drospirenone, a unique progestogen, are
reviewed in this paper. Unlike other progestogens, drospirenone, an analogue of …

Background An association between the use of oral contraceptives and the risk of
myocardial infarction has been found in some, but not all, studies. We investigated this …

Recent concern about the safety of combined oral contraceptives (OCs) with third-
generation progestagens prompted an examination of data from a population-based case …

Acne is one of the most common diseases worldwide and affects∼ 50 million individuals in
the United States. Oral antibiotics are the most common systemic agent prescribed for the …

OBJECTIVE: To assess the contraceptive efficacy, cycle control, tolerability, and user
acceptability of a novel combined contraceptive vaginal ring for up to 13 cycles. METHODS …

Background and Purpose—Epidemiological studies have shown an increased risk of
venous thrombosis in women taking third-generation oral contraceptives, ie, those …

The aim of this study was to investigate the effects of the new estro-progestinic containing
the antimineralcorticoid progestogen drospirenone (DRSP) in women with polycystic ovary …

Abstract 17α-Ethinylestradiol (EE) is widely used as the estrogenic component of oral
contraceptives (OC). In vitro and in vivo metabolism studies indicate that EE is extensively …